- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.12.25 | J&J claims FDA's latest national priority voucher | ||
| 15.12.25 | Kyverna rises on stiff person syndrome data | ||
| 15.12.25 | J&J's run of talc lawsuit setbacks continues | ||
| 15.12.25 | Sanofi gets double blow for MS drug tolebrutinib | ||
| 15.12.25 | GSK closes on approval of asthma hope depemokimab | ||
| 15.12.25 | Sobi pays $1.5bn for Arthrosi to grow in gout | ||
| 12.12.25 | CHMP decision levels the playing field for GSK's RSV jab | ||
| 12.12.25 | UK teams up with Singapore on healthtech regulation | ||
| 12.12.25 | SanegeneBio raises $110m for RNAi, plus other financings | ||
| 11.12.25 | FDA clears first at-home device for depression | ||
| 11.12.25 | Agreement reached on EU's new pharma legislation | ||
| 11.12.25 | Lilly's obesity triple pulls off 29% weight loss in trial | ||
| 11.12.25 | AC Immune says Parkinson's drug slows progression | ||
| 11.12.25 | Pfizer makes first-line case for Tukysa in breast cancer | ||
| 11.12.25 | Roche delivers its data reveal for adjuvant giredestrant | ||
| 11.12.25 | Pfizer's $2bn+ obesity bet, and other weight-loss news | ||
| 10.12.25 | Hims & Hers launches weight-loss business in UK | ||
| 10.12.25 | Are RSV shots next in line for restrictions in the US? | ||
| 10.12.25 | FDA clears first gene therapy for rare genetic disease WAS | ||
| 10.12.25 | UK confirms lower clawback rate for NHS medicines | ||
| 10.12.25 | Antibiotic is first approval in FDA national priority scheme | ||
| 09.12.25 | FDA set to raise bar for clinical trials of CAR-T therapies | ||
| 09.12.25 | Lab-in-a-loop specialist Relation attracts Novartis alliance | ||
| 09.12.25 | FDA backs first AI tool for use in trials, targeting MASH | ||
| 09.12.25 | ASH: Jaypirca matches Imbruvica in first-line CLL trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .